Site Search
You searched for "hepatitis D"
-
Journey to the Cure: Where Can I Find Hep B Info Online? ft. Maureen Kamischke
… Kamischke: So, I think social media is a great way to reach out to different audiences. I think it’s a great way to get the messages out. You know, you can put messages out; you can link back to different parts of our website that really need to be featured and highlighted so that there are areas of what people want to learn more about; and then of course, if you are really interested in the most recent articles in hepatitis B, it’s an easy enough to link out to those so that you are not doing the work for it. Kristine Alarcon, MPH: So, it’s just like another type of way to easily disseminate information and get it more widely available to everyone. Maureen Kamischke: Yes. Kristine Alarcon, MPH: So, you’ve made so many connections across the globe in regard to hepatitis B partnerships, so what do you think the future looks like in the elimination of hepatitis B? Maureen Kamischke: Well, I would have to say that on behalf of myself and all of our friends around the world, we’re all waiting for the cure, but until that time, there’s a lot that we can do. We have a lot of good treatments available. There’s a lot of information that needs to be disseminated. There are a lot of issues with stigma and discrimination. And hopefully, social media can help decrease the amount of stigma and discrimination by educating people, allowing them to learn more about the disease, more about the people that are living with it. It’s devastating the impact of the disease that it has on people, and this is a great way to reach out to them. Kristine Alarcon, MPH: Thank you so much for all your efforts. Be sure to join us on our next episode of “Journey to the Cure.” Just wanted to thank Maureen again for all of her time and all of her efforts in conveying such wonderful information around the world.
http://www.hepb.org/blog/journey-cure-can-find-hep-b-info-online-ft-maureen-kamischke/ -
Aflatoxin Alert: Moldy Nuts and Corn Increases Your Liver Cancer Risk 60-Times If You Have Hepatitis B
Image courtesy of YaiSirichai at FreeDigitalPhotos.net By Christine Kukka One of the biggest health threats to people living with chronic hepatitis B is a toxic, nearly invisible mold called aflatoxin found in corn, peanuts, peanut butter, almonds, Brazil nuts, walnuts and pistachios. People with hepatitis B who eat food with high levels of aflatoxins face a liver cancer risk that is 60-times above average. In addition to nuts and grains like quinoa, aflatoxin can be found in figs, milk and cheese, soybeans, dried spices and cottonseed. It is less common in rice, as long as rice is hulled, which removes aflatoxin mold. This toxic mold, produced by a fungus that grows in warm, moist climates, is found at high levels in crops grown in rural regions of sub-Saharan Africa, Southeast Asia and China, where food storage and processing is not closely regulated. Unfortunately, these regions also have high rates of hepatitis B infection. Low levels of aflatoxins are considered unavoidable in food and animal feed, even when good manufacturing practices are followed. Most countries, including the U.S., allow low amounts of aflatoxin in corn and peanuts. However, some researchers suggest even these low levels can lead to liver damage in people infected with hepatitis B who rely on diets rich in corn, nuts and grains. Image courtesy of sattva at FreeDigitalPhotos.net The U.S. Food and Drug Administration and the USDA has set “actionable limits” (a maximum tolerable level of aflatoxin) for foods like corn and peanuts in order to limit how much aflatoxin reaches the human food chain and livestock feed. "Chemical methods (to remove aflatoxins) have been developed for peanuts, corn, cottonseed, various tree nuts, and animal feeds," according to the FDA's Bad Bug Book's chapter on aflatoxin. "Chemical methods for aflatoxin in milk and dairy products are far more sensitive than for the above commodities because the aflatoxin (in animals) is usually found at a much
http://www.hepb.org/blog/aflatoxin-alert-moldy-nuts-corn-increases-liver-cancer-risk-60-times-hepatitis-b/ -
Make a Vine Video with #HepBUnite for the 2016 Hepatitis B Awareness Campaign!
How do you unite for hepatitis B? VINE TO WIN! Join Hep B United for a national hepatitis B awareness campaign. Create an action-oriented awareness message about hepatitis B through a six-second Vine video! Hep B United will use selected video entries in its social media efforts in May 2016 to help promote Hepatitis Awareness Month. Your video could be included in its national awareness campaign! Eligibility: Anyone and everyone may participate! You do not have to be a member of Hep B United or any organization. What to Do: Use Vine to create a six-second video (click for example) focusing on the 2016 theme “#HepBUnite: How you unite for hepatitis B.” You can create your video alone, or with a group. Your message should focus on how you are united around hepatitis B. You could highlight hepatitis B prevention activities that you participate in, or feature a key fact about hepatitis B in your video. Although not required, Hep B United encourages you to use the materials available from the Know Hepatitis B campaign! How to Enter: Between April 11 and April 29, post your video to either Vine, Facebook or Twitter. Be sure to include the hashtag “ #hepbunite” and tag @HepBUnited. Submit your video link with your name and contact information by e-mail to connect@hepbunited.org. Contest Entry Requirements Each video must be original. Each video must include the hashtag “#hepbunite” and tag @HepBUnited on Twitterand/or Facebook in order to track the videos. Videos should not include any material that would require the consent of any third party or violate any copyright, privacy right, or any other right of a third party. If used, Know Hepatitis B campaign materials should be used in their entirety and retain the CDC and HBU logos. Submissions including offensive language, imagery or themes will be excluded from the competition. Be Creative and Have Fun! Be creative to get across your hepatitis B
http://www.hepb.org/blog/make-a-vine-video-with-hepbunite-for-the-2016-hepatitis-b-awareness-campaign/ -
Barbara Testoni, PhD
Inserm U1052, CNRS UMR-5286, Cancer Research Center of Lyon (CRCL) - France Barbara Testoni is a PI in the “Viral Hepatitis” team at CRCL – INSERM U1052 in Lyon. Her research interests mainly include the investigation of the epigenetic mechanisms at the basis of host and viral gene regulation during HBV infection, with particular focus on the transcriptional regulation of the HBV minichromosome. She is also involved in translational studies, to the aim of understanding the relationships between HBV persistence and intrahepatic innate immunity perturbations and to characterizing new serum biomarkers for intrahepatic cccDNA activity. Read the journal picks of the month from our Emerging Scholars Scientific and Medical Advisory Board here.
https://www.hepb.org/news-and-events/reports/emerging-scholars-scientific-and-medical-advisors/barbara-testoni-phd/ -
Clinical Trials Webinar -What YOU need to know!
Why do we have clinical trials? What is involved with clinical trial participation? How do I find a trial that's right for me? Find out by listening to this webinar from Liver Cancer Connect, a dedicated program of the Hepatitis B Foundation. Presenters Jill McNair of the Center for Information & Study on Clinical Research Participation, and Katelyn Levy, BS, clinical research coordinator at Johns Hopkins Suburban Hospital, explain what clinical trials are and answer frequently asked questions about participating in a trial. https://www.youtube.com/watch?v=IxsubEmdNSE&feature=youtu.be Please refer to our Clinical Trials webpage for clinical trials related to hepatitis B, and liver cancer.
http://www.hepb.org/blog/clinical-trials-webinar/ -
Emerging Scholars Scientific and Medical Advisors
Read the journal picks of the month from our Emerging Scholars Scientific and Medical Advisory Board here. Meet this Hepatitis B Foundation Emerging Scholars Scientific and Medical Advisory Board below. Click on the blue names for more information. We are still in the process of adding some of our Board Members complete details. Please check back for more information. Lena Allweiss, PhD University Medical Center Hamburg-Eppendorf Peter Block, MD, MSc Yale Medicine Julie Dang, PhD, MPH University of California, Davis Rachel Wen-Juei Jeng, MD Chang Gung University Mohsin Khan, MSc, PhD National Institutes of Health Nina Le Bert, PhD Duke Singapore Angel Yen-Chun Liu, MD Chang Gung University, Taiwan Julie Lucifora, PhD (HDR) INSERM, France Udara Perera, DrPH National Quality Forum Ed Pham, MD, PhD Stanford University Tung-Hung Su, MD, PhD National Taiwan UniversityHospital, Taipei, Taiwan Barbara Testoni, PhD INSERM, France Thomas Tu, PhD Westmead Institute, Sydney Eloi Verrier, PhD (HDR) University of Strasbourg Yuchen Xia, MS, Ph.D. Wuhan University Huan Yan, MD, PhD State Key Laboratory of Virology, Wuhan University Mukhlid Yousif, PhD University of Witwatersran
https://www.hepb.org/news-and-events/reports/emerging-scholars-scientific-and-medical-advisors/ -
HBV Journal Review April 2015
HBF is pleased to connect our blog readers to Christine Kukka’s monthly HBV Journal Review that she writes for the HBV Advocate. The journal presents the latest in hepatitis B research, treatment, and prevention from recent academic and medical journals. This month, the following topics are explored: Half of Patients with HBV Genotype C Will Lose HBsAg Five-year Study Shows Tenofovir Dramatically Improves Cirrhosis Tenofovir Also Effective Against Adefovir and Multi-drug Resistance Tenofovir Is Effective in Pregnant Women Who Have Resistance to Other Drugs Estimates of Liver Cirrhosis in the U.S. Jump 50% Taking Antivirals for Three Years After Undetectable Viral Load Reduces Relapse Risk Study Finds Antivirals Can Replace Costly HBIG after Liver Transplant Surgery Hospitalized Hepatitis B Patients Have Higher Death Rates and Longer Stays Than Hepatitis C Patients Small Study Finds Psoriasis Treatment May Not Reactivate Hepatitis B Emulsion Made from Ginkgo Leaves Shows Promise Against Hepatitis B Experimental Treatment Boosts the Immune System and Slows Viral Replication HIV-HBV Coinfected Patients Have High Rates of Hip Fractures April 1, 2015 Volume 12, No 4 by Christine M. Kukka Half of Patients with HBV Genotype C Will Lose HBsAg Researchers predict half of people infected with genotype C of the hepatitis B virus (HBV) will clear the hepatitis B surface antigen (HBsAg) over their lifetimes. This strain of HBV is found primarily in Asia and among Asian-Americans. Clearing HBsAg reduces a patient's risk of liver damage and cancer. In this study, researchers followed 2,121 patients between the ages of 28 and 75 who tested negative for the hepatitis B "e" antigen (HBeAg). Based on the 338 patients who cleared HBsAg over the course of the study, researchers predicted that 56.4% of patients with genotype C would lose HBsAg over their lifetimes, compared to patients with genotype B, who had a 45.7% lifetime clearance rate. In addition to having genotype C,
http://www.hepb.org/blog/hbv-journal-review-april-2015/ -
What treatments (medicines) are available for chronic hepatitis B?
First line treatments include antiviral therapies such as tenofovir (TDF), entecavir and Vemlidy (TAF) which are taken once daily. These antivirals are not a cure for chronic hepatitis B, but they work to suppress or control the virus while you are taking them. When the virus is suppressed, liver disease progression is slowed or even stopped, and the liver is often able to heal with time. It is important to see a knowledgeable doctor to determine if you are a good candidate for treatment since treatment is a commitment, and is taken for at least a year, usually for many years or even for life - or until there is a cure found for this disease. U.S. residents seeking help with medication costs can find resources here. Find more Frequently Asked Questions here. Page updated 02/09/2022
https://www.hepb.org/what-is-hepatitis-b/faqs/what-treatments-medicines-are-available-for-chronic-hepatitis-b/ -
Cinder's Story
Cinder and her husband grew up on a small island in Micronesia, where there is stigma against seeing doctors. Even after they moved to Hawaii and her husband became an advocate for their community, he didn’t want to receive treatment for his hepatitis B. When he became seriously ill, Cinder cared for him every day for two years at the medical center. After he passed away, Cinder took up his mantle in their community by interpreting, volunteering at the church, enrolling people in health insurance, educating others about hepatitis B. Cinder's story is available in English and Chuukese. English Chuukese
https://www.hepb.org/research-and-programs/patient-story-telling-project/cinders-story/ -
Randy's Story
The excitement in Randy’s family over his son Cody’s acceptance to the U.S. Naval Academy turned to disappointment when they learned that Cody has a hepatitis B infection. Even though monitoring and treatment have advanced considerably, the U.S. military does not admit people living with the virus. Randy hopes this policy can be changed, and he continues to support Cody in moving on and embracing a hopeful future.
https://www.hepb.org/research-and-programs/patient-story-telling-project/randys-story/